Clinical Trials Directory

Trials / Completed

CompletedNCT03372161

Corticosteroid Lumbar Epidural Analgesia for Radiculopathy

Corticosteroid Lumbar Epidural Analgesia for Radiculopathy (C.L.E.A.R.)

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
401 (actual)
Sponsor
Scilex Pharmaceuticals, Inc. · Industry
Sex
All
Age
18 Years – 70 Years
Healthy volunteers
Not accepted

Summary

This is a research study of SP-102, an experimental medication designed to relieve pain in patients with a specific type of leg pain. The medication is given once by your healthcare professional, with a possibility of a second injection as early as about 1 month after the first treatment. The purpose of the study is to measure how well a single injection of the experimental medication, SP-102, relieves pain. The study will also investigate the side effects of SP-102.

Conditions

Interventions

TypeNameDescription
DRUGSP-102injection
DRUGPlaceboinjection

Timeline

Start date
2017-12-08
Primary completion
2021-08-20
Completion
2022-01-06
First posted
2017-12-13
Last updated
2022-09-19
Results posted
2022-09-19

Locations

37 sites across 1 country: United States

Regulatory

Source: ClinicalTrials.gov record NCT03372161. Inclusion in this directory is not an endorsement.

Corticosteroid Lumbar Epidural Analgesia for Radiculopathy (NCT03372161) · Clinical Trials Directory